Physician profile
Manmohan Biring
NPI 1770650335
$2,802.10
in general payments reported to CMS, 2019-2025
24 companies · $1,425 in 2025
The $1,425 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $641 · 2020: $198 · 2021: $83.72 · 2022: $52.42 · 2023: $172 · 2024: $231 · 2025: $1,425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $845 · Travel and Lodging: $836 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $845.10 |
| Travel and Lodging | $835.53 |
| Education | $146.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $852.95 | 2019-2025 | |
| Glaxosmithkline, LLC. | $303.36 | 2019-2025 | Nucala |
| Amgen INC. | $289.43 | 2022-2024 | Tezspire |
| Inspire Medical Systems, INC. | $189.70 | 2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.57 | 2019-2025 | Ofev, Jascayd, Spiriva Respimat |
| Regeneron Healthcare Solutions, INC. | $154.42 | 2019-2025 | Dupixent |
| Sunovion Pharmaceuticals INC. | $148.61 | 2019-2020 | |
| Genentech USA, INC. | $122.23 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $101.51 | 2019-2025 | Tezspire, Fasenra |
| Sanofi-Aventis U.S. LLC | $59.80 | 2025 | |
| Allergan, INC. | $52.16 | 2019-2020 | |
| Pfizer INC. | $50.10 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $48.87 | 2019-2023 | |
| United Therapeutics Corporation | $42.50 | 2021 | |
| Veran Medical Technologies, INC. | $35.17 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $34.21 | 2019-2023 | Yupelri |
| Becton, Dickinson and Company | $28.01 | 2019 | |
| Viatris Specialty LLC | $22.95 | 2025 | Yupelri |
| Verona Pharma, INC. | $19.01 | 2025 | Ohtuvayre |
| Teva Pharmaceuticals USA, INC. | $16.34 | 2021 | |
| Baxter Healthcare | $15.27 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Insmed, INC. | $15.13 | 2022 | |
| Csl Behring | $12.95 | 2020 | |
| Philips North America LLC | $12.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manmohan Biring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.